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2005 SPEAKER SERIES:
DR. JOSEPH ROHAN LEX, JR., M.D. FAAEM
THE PHYSICIAN-PHARMACEUTICAL INDUSTRY
RELATIONSHIP
MR. MEARNS: Good afternoon, everyone. My name is Geoff Mearns and I'm
the Dean of Cleveland Marshall College of Law and it's my pleasure to welcome you
here to what I guess is chapter two of the inaugural lecture in the Journal of Law and
Health lecture series.
If you had the pleasure of being here yesterday, you know that you are in for an
informative and engaging presentation by Dr. Lex. And so without any further ado,
I'm going to introduce Evelyn Holmer, she is co-editor-in-chief of the Journal of Law
and Health and she will introduce Dr. Lex.
MS. HOLMER: Good evening. On behalf of the Cleveland Marshall Journal of
Law and Health, I'd like to welcome you here this evening.
Before I get started, as a friendly reminder, if you haven't done so already, if you
could just pull out your pagers, BlackBerries and cell phones, make sure you have
them on vibrate or silent, I would greatly appreciate that.
All right. On to getting started.
Being one of only a handful of law reviews which encompass both the fields of
law and health, the Journal seeks to serve Cleveland and its healthcare community by
facilitating a link between the medical and legal professions. The Journal prides
itself on constantly examining healthcare law from all angles, be it medicinal,
constitutional or political. And in doing this, there are a variety of forums, be it from
presenting speakers to publishing medical works to publishing law reviews. In fact,
a transcript of tonight's presentation will be published in our next issue, numbered
18-2, which is due out in December, knock on wood.
Pursuant to this spirit, it is our honor to host Dr. Lex tonight. Dr. Lex is a
graduate of the University of Texas Health Science Center and served his internship
and residency at the Thomas Jefferson University Hospital in Philadelphia. He is a
member of the Society for Academic Emergency Medicine, a member of the
Physicians for National Health Plan, and also a Fellow of the American Academy for
Emergency Medicine. He currently serves on the faculty at Temple University
School of Medicine as an assistant professor of emergency medicine.
Dr. Lex's educational experience is outmatched only by his list of accolades, and
this is where he's going to get embarrassed because we did this last night. Dr. Lex is
the recipient of the Presidential Unit Citation of Valorous Action in Vietnam, the
Combat Medical Badge for Service in Vietnam, the Temple University Excellence in
Teaching Award, and the Vickery Award for Outstanding Contributions For
Emergency Medicine Education, amongst many others.
Ladies and gentlemen, please join me in welcoming for the second time in our
series Dr. Joseph Lex.
DR. LEX: Do I need to speak louder using the lavaliere? Are you okay if I
wander? Cool. Because I'm going to wander. All right.
Tonight's topic is actually four combined into one. If you thought last night's talk
was truncated, two hours into one, tonight I'm going to cram four hours into one. So
hang onto your hats.
I could actually divide this into four different talks. First of all, there's the ethics
on giving gifts. Then there's the intertwining of academia and industry, which is
pretty nasty, when you get right down to it. Then there's just the whole psychology
of promotion. And finally, food, flattery and friendship. I hope to spend a little bit
of time talking about some logical fallacies in pharmaceutical promotion. So I've got
lots of things to get in here.
First of all, I've got to make confession. Once upon a time, I ate drug rep
doughnuts and pizza. And I craved freebies at national meetings. I used to get my
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little bag and go around, stuff the bag full of stuff. I attended drug company
sponsored meals at one time in my career. I used to drink from a Monistat mug, I
wrote with a Rocephin pen, I did all of these things. I even once, please forgive me,
I went to a Phillies game on a drug company's dollar and I sat in their private box.
But that was a long time ago and I wish that I knew then what I know now. I
have been clean for about fifteen years.
Now, I'm going to give you this: I have knowledge that pharmaceutical research
and development is employing. Ten years ago age was a death sentence. Thirty
years ago renal failure was a death sentence. Fifty years ago cancer was a death
sentence. There have been remarkable strides in the pharmaceutical research,
although much of the research actually comes from universities and is funded
nationally rather than by the pharmaceutical industry. That's a whole different topic.
I will just acknowledge that some good comes out of the pharmaceutical industry.
In addition, it is still happening. Not two days ago Bayer Pharmaceuticals
announced that they were long moxifloxacin, one of their expensive new antibiotics,
to be tested in the treatment of tuberculosis, and if it is found to be successful, they
promised they will distributed it at cost in third world countries to try to eradicate
tuberculosis. So drug companies are doing good things. And I'm not going to argue
that.
My premise is that physician interactions with marketing representatives result in
inevitable and irreconcilable conflicts of interest or the appearance of conflicts of
interest. Our patients in medicine are the ultimate losers from such interactions.
So for recovery we have proposed these things, people who feel the way I do.
We have to admit that we are powerless over pharmaceutical paraphernalia, that our
lives have become unmanageable. We will make a searching and fearless moral
inventory of ourselves, our desks and our work areas. We are entirely ready to
remove all of these defects of character, as well as pens, penlights and notepads.
And having have this spiritual awakening as a result of these steps, we try to carry
the message to others, and to practice these principles in all of our affairs.
Does this sound familiar? What's TANSTAAFL? Who is a Heinlein fan? What
does TANSTAAFL mean? There ain't no such thing as a free lunch. This is a quote.
There ain't no such thing, and if there were, these drinks would cost half as much.
Reminding us anything that is free costs twice as much in the long run or turns out
worthless. This is from The Moon is a Harsh Mistress, 1966, Robert Heinlein.
But I hear you say or I hear my colleague physicians say nearly all organizations
agree that it's okay to take small gifts from the drug companies. Or if, you know, if
they don't market it to us as physicians, they are just going to turn around and market
it directly to the consumer and the consumers aren't going to know how to handle
that information. At least we can process and deal with that information. Or, you
know, you are really an insulting boor to think that I can be bought so cheaply, that if
I can be bought by a pen or a notepad, but you know something, I'm going to remind
you that, as a lawyer and as a physician, we have a fiduciary relationship with our
patients or with our clients. And what does this mean?
A fiduciary, we have a specialized knowledge or expertise, we hold the trust of
others, we hold high standards of conduct, we avoid conflicts of interest, and we are
accountable or obligated, both ethically and legally. This is the place where
medicine and law have the same set of ethics.
I am a member of a profession. As a professional, society has asked that I serve
its interests over my own interests. And in return, society trusts me to do what is
right. This trust allows my profession to self-govern. Just as it allows your
profession to self-govern.
The problem is, when we get into the promotional pharmaceutical, I'll get into
that a little bit more, because most physicians are hard working, and most physicians
desperately want to act in the patient's best interest, physicians do not like the image
of being bought by drug companies. We like to see ourselves as independent
thinkers, and this is not a very popular message among physicians. It's really not.
Because most physicians think they are over all of this stuff that I am talking about.
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But I want to show you something that I hope will make you understand where I'm
coming from.
Companies are businesses, we live in a capitalist society, that's not going to
change anytime soon, and pharmaceutical companies are not evil empires, for the
most part. They are businesses. They are businesses. They are the most profitable
business in the world, by far. They make huge amounts of money, and I'll show you
statistics in a little while. They spend far more on marketing than they do on
research and development, despite what they want to tell you. A majority -- or more
money goes into marketing than it does into research and development, and the
reason they spend the money on marketing is simple. It works.
In fact, as a business, it is their obligation to make as much money as possible for
their stockholders. If the money they put into marketing did not work, it would be
unethical for them to spend it on marketing because it was not returning a profit. So
this is their ethics and this is what we have to look at. It's a different set of ethics
from the fiduciary relationship that we have with our patients or our clients. Their
business is the business of business. It's to make money.
Drug companies do not advertise to capture our forebrains. They advertise to
capture our hands, which write the prescriptions, they capture our subconscious, and
sometimes they capture free advertising space on our shirt, our coffee meg, our pen,
our notepad, our stethoscope. The marketing strategies use proven methods of
promotion. Otherwise they would not be using them. They are aimed at the
subconscious, and they have effects which are unavoidable and unconscious. And
the reason they use them is they work. It's that simple. And doctors don't want to
accept this. It's really not a matter of choice.
Where do we fit in the picture as physicians? We are the ones who write the
prescriptions. We are the ones who are driving the costs of pharmaceuticals.
Healthcare costs are rising at a rate of about ten percent a year and the largest
component of that is the cost of drugs. And we're the ones who write the
prescriptions.
Now, what about conflict of interest? Conflict of interest is defined as a set of
conditions in which judgment concerning a primary interest tends to be unduly
influenced by a secondary influence -- or interest.
So many doctors would be willing to sign this, it is frightening. That stuff
doesn't influence me at all. I just know -- I don't even know what drug is on my pen,
I just go for the free food. So many people would be willing to admit that.
Former Surgeon General Everett Koop, he supported an extended patent for
Claritin a few years ago. The Koop Foundation accepted a grant of a million dollars
from Schering-Plough. What does Schering-Plough make? Claritin.
Okay. Koop was confronted with this information. He said I have never been
bought. I cannot be bought. I am an icon. I have a reputation for honesty and
integrity, and let the chips fall where they may. This is the surgeon general. I like
Everett Koop. Don't get me wrong. I really like Everett Koop. One of his exsecretaries was matron of honor at my wedding. But he's no different from anybody
else. As far as being influenced by this stuff. He said it is true that there are people
in my situation who could not receive a million dollar grant and stay objective, but I
do.
Another quote. Power always thinks it has a great soul and vast views beyond
comprehension of the weak. John Adams, letter to Thomas Jefferson. I think that's
very appropriate to Dr. Koop's comment.
Conflicts of interest are institutional weeds. They take root below the surface,
they become pervasive problems long before they show their ugliness. This is from
the Widener Law Symposium Journal 2001.
I have other quotes. In the interest of time, I'm going to move on.
Are gifts a problem? Yes, they are. What do physicians think about receiving
gifts? This is an internal medicine training program, 90 percent response rate. I
won't bore you with the details. It comes down to this: Physicians were asked
would you have a problem taking these gifts from a drug company? A $40 textbook,
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$40 golf balls, free lunch with a rep, happy hour with a rep, without a rep, would you
have a problem taking this? They surveyed both residents and faculty.
A textbook, no problem. Not even a mild problem. Not even a mild problem.
Golf balls. Well, some people had a mild problem taking golf balls with the drug
company name printed on them.
What about free lunch? No problem.
Free lunch without a rep. Even less of a problem.
Happy hour with drug rep. Maybe a little problem.
Look at this. Look at this. Not one of them even got to be a moderate problem.
So doctors are expecting this and they don't have any problem with it. Older data,
not that old, two years old. But that's a little bit scary. That doctors are so willing to
take this.
Great study. Principles and pens: Attitudes and practices of medical house staff
toward pharmaceutical industry promotions, 2001 study, surveyed 117 young
physicians in training, 90 percent response rate, attitudes towards nine types of
promotion. This is the appropriateness of taking the drugs -- I'm sorry, of taking the
gifts. This is just a survey.
How appropriate do you think it is to take a textbook, a lunch, a pen, a set of
luggage from a drug rep? Very appropriate. Those are the numbers. Fifty-three
percent said it was very appropriate to take an antibiotic guide. Only 80 percent said
it was appropriate to take lunch. That's refreshing. Only one of out of 12 would take
luggage with the drug rep on the side of it. Somewhat appropriate, and not
appropriate.
Okay. This is a survey of attitudes. You know what they did next? They
actually pulled all this stuff out for people. And guess what happened? All the
people who said they would participate took this. These are the people who said that
they would participate even if they considered it inappropriate. These are the people
who said it is not appropriate to take a book or an antibiotic guide, and yet when that
stuff was set on the table, they took it. So the attitudes and what they actually do are
a little different.
This is probably my favorite slide. It's the other guy that I worry about. How
much influence do drug companies have on my practice of medicine? Me and other
guys. Okay? None, sixty-one percent. Absolutely no influence on the way that I
practice medicine. Okay? A little bit, 38 percent. And a lot, one percent said drug
companies affect the way I practice.
Now, what about the other guy? What about the person that I share an office
with or the person I sign out my patients to or the person that I refer my patients to?
What about him? Or her?
None, 16 percent; 51 percent a little; and 33 percent a lot. This is human nature.
We are so willing to put these characteristics on others that we're not willing to
assume ourselves.
Does that sound familiar? It is true that there are people in my situation who
could not stay objective. But I do.
Pharmaceutical promotion. Get some good stuff here. 2004 pharmaceutical
industry spent $21 billion on promotion. That's a B, billion. Direct-to-consumer was
2.6 billion, physicians 18.4 billion. Where did this money go? Well, it kept going
up, as you can see, from 1996. Why does it go up? Because it works.
For physicians, only $480 million, half a billion dollars went into journal ads.
That's only two percent. Detailing to hospitals, 4.1 percent. Detailing to doctors,
notice this is part of promotion, dropping off free samples is promotion, and that's
exactly where it's budgeted, 25 percent. Direct-to-consumer ads, 12.5 percent. And
the rest is in samples. The rest is in samples. Fifty-six percent. Why the samples?
We'll get into that.
Presently there are about 600,000 practicing physicians in the United States. You
do the simple math and you see that the drug companies are spending an average of
$30,000 a year per physician to promote material to them. I don't know who's got
my 30,000. Because I don't take any of it. So somebody got my 30,000. But this is
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how strong the promotion is of the pharmaceutical industry. $30,000 per physician
per year. Imagine what could be done with that money. Imagine what good could
be done with that money.
Direct-to-consumer ads. You know, we are one of two developed nations in the
world that allows direct-to-consumer ads. The other one is New Zealand. There is
no country in Europe that allows direct-to-consumer ads.
Look at how much this cost has gone up. This is the spending. Why has it gone
up? Because it works. It was $2.5 billion a few years ago. It's even higher now.
Radio and billboard, 11 percent. Print, you will notice that direct-to-consumer
ads in print are more than direct-to-physician ads in print. Direct-to-physician ads
were only a half a billion. To the consumers, it's 800 billion. Where is the rest of it?
Television. $1.43 billion spent on television ads for direct-to-consumer advertising.
What are Americans being sold? Article from Lancet in 2001. Sixty-seven ads
were analyzed. Sixty-three percent of the drugs being sold were to ameliorate
symptoms, 26 percent were to treat disease and 11 percent were to prevent illness.
Mostly these are lifestyle drugs. Two-thirds of the ads make an emotional appeal
rather than a logical or a scientific appeal. Two-thirds of the ads. Thirteen percent
described the benefit of the medication using data. Only 13 percent, because the
data's not that strong. Eighty-seven percent described the benefit using vague,
qualitative terms rather than actual scientific data. Only half used data to describe
side effects, and not one of these ads mentioned cost. Not a single one.
So how much of the drug company revenue is spent on each of these aspects?
Twelve percent of revenue goes for research and development. Seventeen percent is
profit that goes out to the shareholders. And 30 percent is in marketing and
administration, and it's clever the way they do this, they combine marketing and
administration together even though the vast majority of this turns out to be
marketing.
Employees in 2000, this hasn't changed very much, distribution two percent,
administration 11 percent, research and development only 22 percent, production and
quality control, a little more, 26 percent. What's the rest? You bet. Thirty-nine
percent in marketing. So that's where the money's going. It's going into marketing.
Pharmaceutical profits. For every industry in the United States, the median profit
as a percent of revenue has been hovering somewhere between two percent and four
percent, three percent and five percent. This is revenue, median profit as a percent of
revenue. The drug companies are in a world by themselves and that is their profit as
a percent of revenue. Up to 19 percent. So they are making big bucks, hand over
fist.
U.S. drug expenditures have been going up year after year. You could just see it
continuing to spiral upwards. Twenty-four percent is a shift toward expensive drugs,
37 percent is due to an increased cost of drugs, and 39 percent is simply due to
writing more prescriptions. Americans are pill takers. This is a pill-taking society.
We had a little conversation, a little discussion about this a couple of hours ago,
trying to figure out exactly why, but it boils down to people want a quick fix. They
don't want a doctor to sit and talk to them for ten minutes and the doctor doesn't want
to waste the time, and be aware of the doctor who reaches for the pen when you
mention a symptom.
Direct-to-consumer spending. Pepsi spent $125 million in 2000. This is on
direct-to-consumer spending. Budweiser spent $146 million. And GM Saturn spent
$169 million. Okay. What's the missing bar in there? 2000. Vioxx. Vioxx spent
more money than Pepsi and Budweiser in promoting the product in 2000, and what
happened to Vioxx last year? Got pulled. Got pulled off the market. But that's how
much money is out there.
Now, where, where do these drugs come from? Industry and research is really
fascinating, and this is really kind of a topic all in itself. But I want to briefly go
through this to try to help you understand. The industry designs and funds studies
which are likely to favor its own products. They analyze their own data, they then
hire ghostwriters to write the articles or to put their name on articles which are
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written by professional medical writers, and if the data is not favorable, they
suppress it being published. It doesn't get published with bad, bad news about
particular drugs.
Here's a study. The Journal of General Internal Medicine looked at 107
controlled trials, they said did the author favor new drug versus old drug or did the
author have industry support, and the trials funded by manufacturers of a new drug
were significantly more likely to favor a new drug.
Cancer drugs. Studies that reached unfavorable conclusions about cancer drugs.
Okay? If they were industry-sponsored studies, only five percent of those studies
came up with negative results. If they were privately-funded studies, 38 percent
showed negative results with cancer drugs.
Authors whose work supported safety of calcium channel blockers were more
likely to be funded by drug manufacturers than authors whose work did not support
the use of these drugs.
I gave a talk at MetroHealth earlier today, I talked a little bit about Norvast,
which is a very expensive blood pressure drug which had been shown in a massive
42,000 patient study to be no better than hydrochlorothiazide which cost $30 a year.
This is an example of that.
We've got three major studies without industry support who have found a higher
risk of blood clots for women who were using third-generation contraceptives.
These are nonindustry-sponsored studies. The three studies that were sponsored by
the drug industry did not show there was an increase in blood clots. Coincidence?
Maybe.
Neurontin. 1994. Neurontin was approved by the FDA as a second-line seizure
medicine, it was approved to be given as a drug in addition to what someone was
already taking to prevent seizures. It was not a first-line drug. In fact, when they
applied for first-line status, they were turned down. However, they did approve it for
posttraumatic neuralgia, which is shingles, pain after shingles. Yet in 2003
Neurontin generated $2.4 billion in U.S. sales. How in the world does a second line
seizure drug generate $2.4 billion and become the tenth biggest seller in the country,
the tenth biggest profitmaker in the country?
Those are the other nine, by the way. You probably recognize the names of some
of them.
Well, there was a supplement to a second line journal which came out and it had
articles justifying the use of Neurontin in all of these conditions. Bipolar disease,
pain syndromes, reflex sympathetic dystrophy, attention deficit disorder, migraine
headache. This was all bad science. Not only that, all of these articles were
ghostwritten, and they hired neurologists to put their name on them. They were all
favorable to the drug company.
The government was not amused. In May of 2004 Pfizer was fined $430 million
for inappropriate promotion for off-label use of Neurontin. Nonetheless, speakers
were paid big money to promote the off-label uses, as I said before, the articles were
ghostwritten, and the fact is, when you got $2.4 billion in sales, a $430 million fine is
just the cost of doing business. Because doctors have not stopped writing for these
unindicated uses, I assure you. I still see patients coming in who are taking
Neurontin for things that it's never been approved for.
Okay. They blinded me with science. How do they do this? Drug companies do
not test their drugs in sick patients. Unless they have got a particular drug that they
want to show works in a particular population. They test their drugs in a healthy
population rather than the patients who may actually end up receiving it. This makes
the drugs appear to have fewer side effects.
And a perfect example of this is the nonsteroidal antiinflammatories. In the
original studies for nonsteroidals, one in 50 patients was over the age of 65. Yet this
is the primary group that doctors are writing for, the over 65 patients. And once the
older patients started taking them, the side effects showed up, the adverse effects, the
GI bleeding, the other problems.
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Trials are designed in certain ways to make the end results look good. They use
surrogate endpoints. In other words, they may use an endpoint for a breathing
medicine of an FEV-1, which is a measure of pulmonary function. That's a surrogate
endpoint. A more useful endpoint might be how many times did this patient have to
be hospitalized? That's something that is usable. Other usable endpoints are things
like death, stroke, heart attack. But so often you will see these studies using
surrogate endpoints.
In the cardiovascular work you are going to see a lot of reference to what is
called TIMI III flow. Based on a study done years ago, the TIMI III trial talks about
blood flow through coronary arteries. That's a surrogate marker. Nobody talks about
increasing -- or decreasing mortality because that data didn't work. It didn't decrease
mortality. It just improved the flow in the coronaries.
Important endpoints, as I mentioned before, death, disability, prolonged hospital
stay, adverse effects.
They will do strawman comparisons. This is one of the favorites. They will take
a good dose of their drug and compare it to a low dose of another drug and say, well,
our drug is obviously better. They do this all the time. You have to be cautious and
look at the doses of the drugs they are using in the study.
Here's a study that looked at all the NSAID studies and discovered, guess what,
whoever sponsored the study always got a better result than the comparator. In 48
percent of trials, the reason for that was because the dose of the sponsored drug was
appropriate and the dose of the drug that it was being compared to was less than
appropriate. The strawman study.
You can get the results you want by doing a lot of things, if you are a drug
company. You can do a trial against placebo. To get a drug approved by the Food
and Drug Administration, you don't have to prove it's better than anything else. You
have to prove it's better than nothing. You do not have to prove that it's better than
anything else that's on the market. So a lot of these studies are done with placebo
trials. Or they will do a trial against an inferior treatment, a trial against a low dose,
like I mentioned before. Or they will do a trial against a high dose if they are trying
to prove there's less toxicity with their drug. They will have what's called an
equivalence trial which is too small to show the difference from the competitor drug.
One of my favorites was the composite endpoints. They will say, well, we
looked at this drug and we decided the endpoint was death or stroke or heart attack
or toenail fungus. And we decided that this drug reduced the end component. Okay?
Well, if you look at the individual data, you may find out it didn't make a bit of
difference in death or stroke or heart attack, but it did a whale of a job taking care of
toenail fungus. So that's how they got that result, by using the composite endpoints.
It's the principle that if you set up four targets at the other end of the room and you
are not a very good shot, you are more than likely to hit one of those targets.
Subgroup analysis. Always dangerous. There was a subgroup analysis of a
major cardiology trial a few years ago, huge trial, 40,000 people, and by looking at
the subgroup analysis, they proved that if you were a Libra or a Gemini, aspirin
didn't work if you were having a heart attack. I'm serious. That's the danger of
doing subgroup analysis. You can make numbers dance and sing. This is why
subgroup analysis is also called data dredging. That's another name for it. Data
snooping. Because we have got such fantastic computers and software nowadays
that we can plug in all these numbers and we can make something look significant.
That's not science. Science is determining what you are going to do at the beginning
and sticking with it. It's not going back and dredging through the data and seeing
what looks significant.
And then the other thing they do, how many times do physicians actually get to
read negative studies? There are file cabinets across this country full of negative
studies that never got published. Because nobody wants to publish a negative study.
Where's the glory in that? Where's the glory in saying I spent four years of my life
and proved that two things were exactly the same? So that type of stuff doesn't get
published.
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Something else they do is they will publish the same study, a positive study, in
several different journals or in supplements, they will publish different outcome
measures at different times.
This is one of the complaints with Celebrex. The initial article in the New
England Journal on Celebrex said that at three months there was less GI bleeding.
What they didn't tell you was that they had data out to six months and at six months
there was absolutely no difference in GI bleeding. Until the Washington -- I think
one of the Washington newspapers actually dredged that data up.
These are just some other examples of the way you can take data and make it
dance and sing and make it do the things you want. You have to be very cautious.
Physicians have to be very, very careful about this material.
All I know is what I read in the journals. Right? Well, quote from the New York
Review of Books. Journals have devolved into information laundering operations
for the pharmaceutical industry. That's a shame. That's a shame.
In 1987, the manufacturer of levothyroxine, Synthroid, contracted with a
University of California researcher, they paid her to compare their product with the
generic forms of thyroid that were on the market. She did the data, she did the work,
it was a beautiful study, it was an elegant study, and she proved there was absolutely
no difference between Synthroid and all of those generic thyroids that were on the
market.
The company not only refused to allow the findings to be published, they sued
her when she tried to published them independently. And this was the subject of a
huge brouhaha several years ago. It ended up as a separate article in the New
England Journal called Thyroid Store. Which is a good pun, actually.
The Immune Response Corporation contracted with UCSF performed
randomized controlled trials for the immune modulator to treat AIDS. It showed no
effect, and when the researchers tried to publish these results, they were again
stopped by the company. They said you cannot publish that data. We did not
approve it. Even though they hired them to do true scientific work.
1996, deferiprone, used to treat thalassemia major, could worsen hepatic fibrosis,
in other words, some liver problems. And the trial sponsor threatened, again, legal
action, we will sue you if you publish this information, which we hired you to
research, by the way. So there's example after example of this.
This is one of my favorites. 106 reviews of passive smoking, of which 63
percent said it was harmful and 37 percent said it was harmless. Well, they did a
multiple regression analysis, they looked at the quality and the peer review and the
year of publication and everything else, the only factor which fell out was whether
the author was affiliated with the tobacco industry or not. That was the only thing
that made a difference.
Survey, 192 authors of 44 clinical practice guidelines, 87 percent of the authors,
this is clinical practice guidelines, this is what we're supposed to treat patients based
on, the best evidence available, 87 percent of the authors had some form of
interaction with the pharmaceutical industry. And yet in the published versions of
these guidelines, specific statements about personal financial interactions were made
in two cases.
There are better examples of this. The American Heart Association, this was a
big, big problem, Class I, which means definitely recommended, tPA for stroke,
despite controversy about its safety, about its efficacy that is still raging in the
emergency medicine and the neurology community, yet the American Heart
Association made it a Class I recommendation with its last update.
Most of the American Heart Association stroke experts have undisclosed ties to
Genentech, the manufacturers of tPA, and Genentech contributed more than $11
million to the American Heart Association in the ten years before the AHA
recommendation. If you go to the American Heart Association headquarters on
Greenville Avenue in Dallas for a meeting, you will go to the Genentech Meeting
Center, which is named for the drug company which contributed the money. And
that is a shame.

2003-04]

THE PHYSICIAN-PHARMACEUTICAL INDUSTRY

331

Now, when the original recommendations came out, they said tPA saves lives.
The data does not show that. And enough people protested that they got the
American Heart Association to pull that. It does not save lives. Thus, even a
seemingly impartial nonprofit organization that issues professional guidelines that
we have to follow and that lawyers look at to determine whether somebody has
committed malpractice, these guidelines can be bought.
The flak man cometh. Now we're going to talk about detail a minute.
How we doing on time?
Okay. Physicians have been characterized into four different types. There are
the sheep who are primarily interested in maintaining conformity. There are the
wolves, who are primarily interested in making money. And we have got these in
our profession just like you've got those in your profession. There are the bunnies,
and I'm a bunny, we like taking care of sick people. That's what we do. And then
there are the dodos, and the dodos are the burned out, and their primary concern is
survival.
Now, the reason that this is important is because in the pharmaceutical
promotional magazine Scrip you will see a takeoff on the musicians of Bremen with
the wolf and the sheep and the bunny and the dodo, and this particular issue tells the
pharmaceutical representatives how to approach each of these categories of
physicians. Because the approach will be different for each one of them.
Promotional honesty. What about the materials that a drug rep actually hands
out? What's the appropriateness and what's the value of it? This is a study where
they looked at all materials left behind by drug reps or mail over a seven-month
period. 482 pieces of promotional material. They looked at it scientifically, they
said does it meet the FDA requirements for balance, adequate instructions for use,
and discussion of approved uses only, and lo and behold, they discovered that about
a third of it lacked fair balance, nine percent lacked instructions, and even four
percent, one in 25, talked about unapproved uses, which is very much verboten. The
FDA does not like it if you promote drugs for off-label use. Forty-two percent of
this material failed to comply with at least one FDA criterion for promotional
material from drug companies to doctors.
What about the accuracy of information from pharmaceutical sales
representatives? Article in JAMA about ten years ago, this is a house staff
conference, it's standard in every academic program in the country, there was a
pharmacists in the front row with a tape recorder and he recorded all of the
comments made by drug reps prior to the faculty lecture. Some places still do this.
Before the lunch conference, the lunch is purchased by a drug company, and they
allow this drug rep to stand in front of a group, like this, and show their product.
This pharmacist sat in the front row, he recorded this, and then he analyzed 106
statements made by drug reps at 13 different conferences and classified what they
said as either accurate or inaccurate.
Every inaccurate statement that was made was favorable to the drug. Every
inaccurate statement was favorable to the drug. There were 11 percent of the
statements that were made that were just flat out inaccurate. And the scary thing is
the residents at these conferences remembered 26 percent of those inaccurate
statements as being accurate.
How about the journal inaccuracy? Pharmaceutical advertisements in leading
medical journals. This was actually kind of clever. 109 ads which were submitted in
peer reviewed journals. They took the peer reviewers and they said if this ad were
submitted as an article, would you publish it? This is just going through some of the
criteria. I don't expect you to read these. Thirty percent, 30 percent of these
submitted ads disagreed -- I'm sorry, the data disagreed with the ad claim. I'm a little
ahead of myself on this. Thirty percent disagreed with the ad claim, 44 percent
would lead to improper prescribing, 57 percent of these ads had absolutely no
educational value, and 92 percent, the ad was not in compliance with one or more of
those FDA criteria that I just ran by you.
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This is, this is the one I was thinking of. I was one ahead of myself. Would you
accept this ad in its present form, would you accept this ad with minor revisions,
with major revisions, or would you reject this advertisement? This was presented to
peer reviewers, the ads. Eight percent said they would accept the ad as is, 34 percent
accept with minor revisions, 34 percent with major revisions, and 24 percent would
reject the ad based simply on the science. Because it wasn't scientifically valid.
Let me move through, I want to mention this one, my favorite phrases in
pharmaceutical promotion.
Unsurpassed efficacy. Now, that sounds good. Unsurpassed efficacy. Wow.
Think about what that means. Unsurpassed means just as good as. And yet you will
hear drug reps talk about unsurpassed efficacy of their drugs all the time, now. All
that means is it's just as good as what else is out there on the market. It doesn't mean
it's any better. It's just fancy words to say the same as.
Zyprexa. Zyprexa was approved for treatment of schizophrenia and maintenance
treatment of schizophrenia, treatment of acute mania associated with bipolar disease,
and maintenance treatment of bipolar disorder. Those are the only four indications
for Zyprexa. And yet in 2002 this was the single largest medication expense for
Medicaid programs in Kentucky, Indiana and Tennessee.
Now, what do those three states have in common? Kentucky, Indiana,
Tennessee. They're all lumped together. Who makes Zyprexa? Eli Lilly. Where's
Eli Lilly's home? Indianapolis, Indiana. Probably just a coincidence, right?
The Kentucky legislature considered excluding Zyprexa from payment because
the indications weren't there. Two nonprofit citizen groups sprang into action, they
had rallies at the state capital, they had fax campaigns, they had full ads, full page
ads in the newspapers, and guess what? Eli Lilly paid for the buses, they paid for the
faxes, they paid for the newspaper ads.
Zyprexa in 2003 sold $3.2 billion as an antipsychotic for schizophrenia and
bipolar disease. Those are the only indications for that drug. And yet it sold $3.2
billion.
So where's the government in all of this? Well, let's see. Former President
George Bush is a member of the Eli Lilly board of directors, Ken Lay is a member of
the Eli Lilly board of directors, director of management and budget Mitch Daniels
was Eli Lilly's vice president, and Homeland Security Advisory Council member
Sidney Taurel is the CEO of Eli Lilly. So where is the government in all of this?
And then there's Provigil. Provigil was approved by the FDA for narcolepsy.
And then in 2003 the Primary Care Companion in the Journal of Clinical Psychiatry
dedicated to medical conditions characterized by fatigue, depression, executive
dysfunction, shift work sleep disorder, which all ER docs suffer from, shift work
sleep disorder, because we are shift workers, and this was a supplement which was
published in the journal that paid the lead authors of all eight articles in the
supplement, and Provigil is now being promoted to ER docs as a treatment for shift
work sleep disorder. It's actually been approved for that indication now. It's not
been approved for the other indication.
There's lots of other examples. COX-2s, I'll briefly mention them, but the point
is The Washington Post is the organization that the FDA had the full results of the
CLASS study about Celebrex causing just as much GI bleeding in six months, and it
was never, never promoted. It was never -- Pfizer continues to use earlier reprints of
the bad study, which has now been rejected, and many family docs don't realize that
there's newer data out there that show Celebrex is no better than the cheaper stuff.
Celebrex is two bucks a tablet, ibuprofen is about a nickel a tablet, and they are
about the same as far as side effects.
Then there was the VIGOR study in the New England Journal in 2000 which
showed that Vioxx seemed to show cardiovascular toxicity. 2000. What the
company claimed was that the comparator was cardioprotective, not that Vioxx was
poisonous. And yet the comparator had never been shown to be cardioprotective.
And, of course, a few years later they just pulled it off the market. Long-term trial
confirmed cardiovascular toxicity. So this stuff is still going on.
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Reprints are a big problem. Drug companies may buy as much as a million
dollars' worth of reprints from journals. Now, journals have to sell ad space so they
can put their material out. Physicians, I hate to tell it to you, but physicians are
cheap. Physicians don't want to pay 150 bucks a year for a subscription for
something. They will pay less than that, but to get it for less than that, that means
that the journals have to sell space to the drug companies.
So these are a major source of revenue for the journals which publish the trials.
These are handed out to doctors all the time. The doctors never read them. But they
are handed out, and somehow this journal article branded, it sells, it adds luster to the
selling points. There's a major conflict of interest for journals. Because sometimes
what they have is publish this paper and get a million dollars for reprints or lay off
six editors. Major conflict of interest.
It's a major source of revenue, especially for the second tier journals, and it often
includes papers presented at drug-sponsored symposia, the editors are often the
people running the symposia, it's just all mixed together. And then the studies are
only selectively published. So it's a real mess. You've got to pay attention to stuff
like this.
I'm going to go -- we're running out of time. I want to show you this. This is a
logical fallacy. There are many logical fallacy in pharmaceutical promotion. I want
to show you the fallacy of celebrity. I love this.
Once-a-day Prinivil for blood pressure. Just like Cal Ripken. Both on the job
every day. What's that little bitty print down there that says Cal Ripken, Jr. is not
hypertensive and is not taking Prinivil. It's there, but you've got to look for it. But
you have heard the ads.
Mickey Mantle was promoting Voltaren before he died. Lauren Bacall is out
there promoting drugs. It's the fallacy of celebrity. You know, if Brad Pitt takes this
drug, then I should be taking it also and I'll be more like Brad Pitt. Now, it may be a
bad example, I don't know.
What do our patients think? Well, I know what the cartoonists think. You can
find cartoons like this all over the place. And this certainly makes our profession
look bad.
These used to be posted around hospitals. What do my patients think when they
see that I can go to the AstraZeneca and pick up my Easter ham just by listening to a
drug rep give me a little spiel? Or the Floral & Dash. Unfortunately this is another
AstraZeneca. I'm not picking on them. Those are just two examples that I have.
Now, I am not a friend of big pharma. But you know something, I still get stuff
like this. This is from earlier this year. They are going to invite me to the RitzCarlton Hotel in Washington, D.C., and pay me $1,500 to sit there and listen to some
drug rep talk to me and try to convince me to push their drug. I took out some of the
identifiers there, but I just wanted to show you that this stuff still goes on, even for
somebody like me who has been talking against this stuff for years.
Patient perceptions. Let's just say that the patients recognize what's going on and
they don't like it. They don't like it.
Now, let me go through and get to some other ones, because, as I said, this is a
huge amount of material.
This is a great quote and, from all places, USA Today. Such gifts would trigger a
big red bribery alert in the mind of just about any public official or government
contractor, but not in the minds of many doctors, raking in jaw-dropping gifts from
pharmaceutical firms.
We just sort of accept it as a matter of course. And I think we need to change
this.
And if you are curious about more information, there are so many books out
there, it will make your head spin. These two are probably my favorites, the Marcia
Angell and the Jerry Avorn. The Truth About Drug Companies, Powerful
Medicines. If you go to Amazon.com and you put one of these in, it will tell you
people who bought this book also bought these others. On the Take: How
Medicine's Complicity With Big Business Can Endanger Your Health.
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Jerry Kassirer was an editor for the New England Journal. Marcia Angell was an
editor of the New England Journal. These are not smalltime people trying to make a
name for themselves. These are people who were in the business who saw what was
happening and then decided to expose it when they got out.
Overdosed America, John Abramson. It goes on and on. The $800 Million Pill,
The Big Fix. There are plenty of books out there, all published in the last couple of
years.
It is 6 o'clock. I am going to stop here. I've got a bunch more. This is actually as
many as, I think I've got 292 slides, and there's absolutely no way I can get through
those even in two hours, but I hope that I was able to get my point across to you.
This is a big problem for medicine that we're trying to deal with, I hope a little at a
time. There are a few of us out there who are preaching the message to other doctors
and trying to get them to understand how pervasive this is and how important it is.
I hope it was helpful for you to understand a little bit, as a lawyer, to understand
what influences doctors are coming under here, but also to see what the drug
companies are doing. And again, to emphasize the point, that I don't consider drug
companies to be evil empires. I consider them to be businesses who are following
their own ethics, which are different from our ethics. And we have to keep in mind
our patients or our clients and not profits, which is what they are involved in doing.
So yes, sir.
PARTICIPANT: Okay. I enjoyed your lecture, first of all [inaudible].
Secondly, I think at the beginning you said about how drug companies give away
freebies based on drug samples to physicians.
DR. LEX: Yes. Okay.
PARTICIPANT: Now, what is the harm in that? Because they can't sell it to
the patients.
DR. LEX: No, what happens is -- if you are willing to stay. I understand people
have to leave, but the harm is -- where is it? Okay. The effect of drug sample
availability on physician behavior. They looked at a series of doctors and gave them
hypothetical scenarios, uncomplicated urinary tract infection, high blood pressure,
and depression. They then surveyed the doctors and said what would you use to treat
these conditions? I would use a diuretic or a beta blocker as initial therapy. Ninety
percent of the doctors said that. Okay? This is correct. This is what the ALLHAT
study showed. Hydrochlorothiazide, a diuretic, is the appropriate drug to start
somebody on.
Then when they made samples of more expensive drugs available by freebies, 32
out of those 35 doctors gave a more expensive sample than the inexpensive drug they
would have started somebody on. Okay. Well, what's the point to be made there?
Hypertension followup, patient now has health insurance, the blood pressure has
been controlled on the sample drug. The blood pressure probably would have been
controlled on the cheap drug also. But now that it's controlled on the sample drug, a
prescription is written for that sample medication 69 percent of the time. They did
not switch back to the sample or back to the hydrochlorothiazide.
Sample users wrote for a drug different from the one that they predicted they
would use 88 percent of the time when those samples were available. And that is
why drug companies do it. They do it because they know physician behaviors, they
know that physicians will continue to write for that drug when the patient is able to
pay for something more.
I've got more material on that. I want to show you something else, when you say
what's the harm in the samples. This is one of my favorites.
Personal use of drug samples by physicians and office staff. So you have got all
these free samples sitting in the office. How many of those actually get handed out
to patients? Well, a lot of people help themselves. Twelve faculty, 21 residents,
eight nurses, nine office staff, and three unknown took drug samples. Okay? 230
samples were taken. 152 were for personal use and 78 percent were to give to a
family member. Hmm. Okay. Cost of the samples was about $10,000.
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Now, this is even better. This is pharmaceutical reps with their samples. Do they
use their own samples? Not only do they use their own samples, 59 percent of them
provided samples to other than physicians, so they are prescribing drugs without a
license, and 48 percent either self-medicated or provided samples to friends or
relatives. So half of the drug reps are handing out their drugs to nonphysicians.
Twenty-six percent were swapping with other drug reps. Ooh, yeah, you have got
some Avelox. I'll trade you some Celebrex for your Avelox. And they were
swapping these drugs back and forth.
So this is the problem with samples. Samples lead to bad prescribing. They do
not do our patients any favors.
I work in an emergency department. I have a very financially vulnerable
population of patients. And I try to write for the cheapest possible drug I can write
for on a day-to-day basis, because there's no benefit in me giving somebody a drug
which is going to cost $120 a month if they have to continue on that drug, and if I
give them a sample for one of these drugs and they go to their family doc and their
family doc finds out that drug is working, the inclination is to keep prescribing that
same drug. And that patient cannot afford that drug.
So that's why samples are bad. That's why samples are bad.
Okay. Other questions? Okay. Thank you. Yes, sir.
PARTICIPANT: I was just going to say are pharmacy benefit managers
countering the efforts of branded drugs by pushing generic? It seems -DR. LEX: Oh, absolutely. Yeah, pharmaceutical benefit managers, yeah. We're
asking the wrong questions in this country. The government is asking the wrong
questions. Instead of saying how are we going to pay for drug benefits for the
elderly, we should be asking the question which drugs are useful in the elderly?
Because I think three-quarters of them are useless or possibly even harmful. And I
think pharmaceutical benefit managers may be the people to ask those questions.
They should not be saying how could I cut costs, they should be saying which of
these drugs is actually going to help the people who are in my plan? And I think that
should be the government's job also, but the government is not prepared to take that
up. Instead they are trying to find ways to finance giving bad drugs to people. Or
giving useless drugs or giving expensive drugs to people. But I don't think those are
the answers. I really don't.
Yes, sir.
PARTICIPANT: She just turned around.
DR. LEX: Oh, yes. Hi.
PARTICIPANT: Yeah, I was very interested in the outcome of the lawsuits to
suppress the scientists who have done studies that were not favorable. Were they
able to do it?
DR. LEX: They were not. Because the publicity got out and the general uproar
from the medical community was such that the companies dropped the suits.
PARTICIPANT: Yeah, but in other words, the authors were still harassed by
the pharmaceutical companies?
DR. LEX: Oh, absolutely. Absolutely. Especially Dr. Dong, the physician who
did the thyroid, she was actually fired from the University of California and had to
sue to get her job back. Because of all of the grief that was brought down on the
University of California. And that was a real mess.
PARTICIPANT: I believe that.
DR. LEX: It's very instructive to go read that article in New England Journal
called Thyroid Store. It walks through the entire process of what happened.
Okay. Yes, sir.
PARTICIPANT: You mentioned the use of subgroups for getting drugs
approved. I remember a month or two ago there was a big hubbub over a drug that
was coming out and it hadn't been approved because the data wasn't there, then they
went back and looked at it and they thought that they were getting it approved for
use in the African American community.
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DR. LEX: Yes, BiDil. BiDil. That's a perfect example of subgroup analysis.
That's exactly what happened. They had this combination drug, a diuretic and an
ACE inhibitor, and when they did the initial studies, it didn't seem to offer any
benefit over anything else except when they did a subgroup analysis and saw that in
the African American community it seemed to be more cardioprotective.
The interesting thing is there's another drug, the statins, the statins actually
seemed to work better in preventing cardiac disease in asymptomatic African
Americans, but nobody is going out of their way to promote that right now. The
statins are such big sellers anyway. I mean everybody, gee, people are taking Lipitor
and all these other drugs like crazy. The data's kind of weak. Unless you have
already had a cardiovascular event. In fact, there's pretty good data that unless you
have a cardiovascular event, they don't do anything. Except in African Americans.
And there it does seem to decrease the amount of cardiovascular disease.
Yeah, they made it sound like it was racially tailored, but it wasn't. It was, I think
it was more of a result of subgroup analysis.
DR. LEX: Thank you.

